Kurs
+2,87%
Likviditet
0,01 MSEK
Kalender
| Est. tid* | ||
| 2026-08-27 | 18:10 | Bokslutskommuniké 2026 |
| 2026-05-28 | 18:10 | Kvartalsrapport 2026-Q3 |
| 2026-02-26 | 18:10 | Kvartalsrapport 2026-Q2 |
| 2025-12-05 | N/A | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2025-12-05 | N/A | Årsstämma |
| 2025-11-27 | 18:10 | Kvartalsrapport 2026-Q1 |
| 2025-08-28 | - | Bokslutskommuniké 2025 |
| 2025-06-26 | - | Extra Bolagsstämma 2025 |
| 2025-05-29 | - | Kvartalsrapport 2025-Q3 |
| 2025-02-27 | - | Kvartalsrapport 2025-Q2 |
| 2024-12-30 | - | Årsstämma |
| 2024-12-09 | - | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2024-11-22 | - | Kvartalsrapport 2025-Q1 |
| 2024-11-19 | - | Extra Bolagsstämma 2024 |
| 2024-08-29 | - | Bokslutskommuniké 2024 |
| 2024-05-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-02-22 | - | Kvartalsrapport 2024-Q2 |
| 2023-12-18 | - | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2023-12-15 | - | Årsstämma |
| 2023-11-23 | - | Kvartalsrapport 2024-Q1 |
| 2023-08-24 | - | Bokslutskommuniké 2023 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-02-23 | - | Kvartalsrapport 2023-Q2 |
| 2022-12-16 | - | Årsstämma |
| 2022-12-02 | - | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2022-11-24 | - | Kvartalsrapport 2023-Q1 |
| 2022-08-25 | - | Bokslutskommuniké 2022 |
| 2022-05-25 | - | Kvartalsrapport 2022-Q3 |
| 2022-02-24 | - | Kvartalsrapport 2022-Q2 |
| 2021-12-14 | - | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2021-12-13 | - | Årsstämma |
| 2021-11-25 | - | Kvartalsrapport 2022-Q1 |
| 2021-08-26 | - | Bokslutskommuniké 2021 |
| 2021-05-27 | - | Kvartalsrapport 2021-Q3 |
| 2021-02-25 | - | Kvartalsrapport 2021-Q2 |
| 2020-12-28 | - | X-dag ordinarie utdelning ODI 0.00 SEK |
| 2020-12-14 | - | Årsstämma |
| 2020-11-27 | - | Kvartalsrapport 2021-Q1 |
| 2020-08-27 | - | Bokslutskommuniké 2020 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025.
The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company's stock to facilitate trading. The agreement with Parteo has now been terminated and will expire on March 14, 2025.
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.